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BACKGROUND:  The  male  breast  cancer  (MBC)  is a rare and  represents  less  than  1%  of all  malignancies
in  men  and  only  1% of all breast  cancers  incident.  We  illustrate  the  experience  of our team  about  the
clinico-pathological  characteristics,  treatment  and  prognostic  factors  of  patients  treated  over a period  of
twenty  years  .
RESULTS: Forty-seven  patients  were  collected  1995–2014  at the Breast  Unit of the  Hospital  of Terni,
Italy.  The  average  age  was 67  years  and  the  median  time  to diagnosis  from  the onset  of  symptoms  was  16
months.  The  main  clinical  complaint  was  sub  areolar  swelling  in  36,  76%  of  cases.  Most  patients  have  come
to  our attention  with  advanced  disease.  The  histology  of about  ninety  percent  of the  tumors  were  invasive
ductal  carcinoma.  Management  consisted  mainly  of  radical  mastectomy;  followed  by  adjuvant  radiother-
apy and  hormonal  therapy  with  or without  chemotherapy.  The  median  follow-up  was  38  months.  The
evolution  has  been  characterized  by  local  recurrences;  in  eight  cases  (17%  of  all  patients).  Metastasis
occurred  in  15 cases  (32%  of all  patients).  The  site  of  bone  metastases  was  in eight cases;  lung  in  four
cases;  liver  in three  cases;  liver  and skin  in  one  case  and  pleura  and skin  in  one  case.
CONCLUSION:  The  male  breast  cancer  has many  similarities  to  breast  cancer  in  women,  but  there  are
distinct  functions  that need  to be  appreciated.  Future  research  for  a better  understanding  of the  disease
should  provide  a  better  account  of genetic  and  epigenetic  characteristics  of  these  forms;  but,  above  all,
epidemiological  and biological  cohorts  numerically  more  consistent.
© 2016  The  Authors.  Published  by  Elsevier  Ltd.  on behalf  of IJS  Publishing  Group  Ltd.  This  is an  open
he CCaccess  article  under  t
. Introduction
Even if rarely, breast cancer (BC) affects men. To date, in West-
rn countries, male breast cancer (MBC) is <1% of all breast tumors
nd <1% of all cancers in men  [1–3]. Its incidence is approximately
ne case per 100,000 man-years [4]. Recent epidemiological stud-
es suggest that the incidence of MBC  is increasing by 1.1% per year
1,2]. MBC  incidence is generally low compared with the female
C (FBC), but there is substantial variation between countries. The
ighest overall rates adjusted for age occur in Israel (1.08 per
00,000 person-years), while the rates are the lowest in South-
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east Asia, particularly in Thailand (0.14 per 100000 person-years)
[4]. The reason for this variability is to be found mainly in the
genetic susceptibility for the population. Common factors BC risk,
such as genetic, hormonal and environmental factors, are involved
in the pathogenesis of BC in women as in men. The main predis-
posing factor MBC  is a positive family history (FH) of BC. Patients
with a positive ﬁrst degree FH have a 2.0 times greater risk, which
increases to more than 5.0 times with the number of affected rela-
tives and relatives of the ﬁrst onset, thus suggesting an important
role of genetic factors in the risk of MBC  [5]. From an epidemiolog-
ical point of view, the male breast cancer MBC is similar to the
female postmenopausal and, in general, treatment MBC  follows
the same indications postmenopausal FBC. However, the clinical
and pathological features of MBC  do not exactly match those of
the FBC and this would explain why  mortality rates and survival
are signiﬁcantly lower in male than in female patients [6]. And
now estimated that up to 10% of all the MBCs are hereditary forms
caused by germline mutations in inherited well identiﬁed suscep-
tibility genes BC. With their mutation frequency and extent of
Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
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heir impact in BC susceptibility, these genes can be divided into
high penetrance”, “moderate penetrance” genes and “low pene-
rance”. Mutations in two genes leading BC high risk, BRCA1 and
RCA2, occur infrequently in the population, but give it a high risk
f BC for the individual [11,7]. The moderate risk of BC is deter-
ined by genetic variants associated with BRCA1/2 pathways in
NA repair. These variations occur in <1% of the population, and
heir contribution to the risk of BC is <5% [12,8]. Recently, has
een identiﬁed third class of low penetrance susceptibility alle-
es. The low penetrance, however, makes their function of onset
f the disease still barely comprehensible. Doubtless, BRCA1 and
RCA2 are the major susceptibility genes in high-risk families. In
ases MBC, BRCA2 mutations are much more common than BRCA1.
hese are responsible for 60–76% of MBC  occur in high-risk fam-
lies, while the frequency of BRCA1 mutations varies from 10% to
6% [13,9,14,10]. The vast majority of BRCA1/2 mutations are trun-
ating mutations; however, it was also identiﬁed a large number of
issense variants. At present, there is no evidence of a correlation
etween the position of the mutation in the BRCA1 or BRCA2 gene
nd the risk of MBC. BRCA1/2 polymorphic variants may  also be
ssociated with an increased risk of BC [16,11,18,12]. Interestingly,
s there is an association between the variant BRCA2 N372H and
he risk of MBC  in young men  [19,13]. Speciﬁc mutations in BRCA1
nd BRCA2 show high frequency in speciﬁc countries or ethnic
roups, in particular, genetically isolated populations; This would
xplain the higher incidence (>2% in total) in the Ashkenazi Jewish
ale population than the general population of the United States
20,14,21,15]. Recently were studied speciﬁc BRCA-associated phe-
otypes otherwise identiﬁed in MBC  [31,16]; it was discovered that
ost of the MBC  BRCA1-related are negative HER2 (HER2), and
rade 3 tumors show high proliferative activity. In the study that we
ropose, we evaluated the clinical pathological characteristics, bio-
ogical and genetic implications, treatment and prognosis of cases
f MBC  treated in the Breast Unit of the Hospital “Santa Maria” of
erni in a period of about twenty years.
. Patients and methods
.1. Clinical data
It was performed analysis regarding cases of MBC  treated
n twenty years in a single center. Inclusion criteria were male
atients >18 years with localized breast cancer, locally advanced
r metastatic. We  excluded from the study patients who had no
ollow-up after initial diagnosis. All the diagnosis of breast can-
er had preoperative histological conﬁrmation; tumoral staging
as performed with the 2007 edition of the TNM classiﬁcation.
he tumor histological classiﬁcation was performed using the
carff-Bloom and Richardson (SBR) system histology. Immuno
istochemical analysis to determine the estrogen (ER) and pro-
esterone receptor (PR) status was performed using standard
rocedures on 4 micron parafﬁn sections of tissue samples stained
ith the monoclonal antibodies 6F11 and 1A6 for ER and PR, respec-
ively. 10% nuclear staining was considered a positive result. The
escription of the clinical data was produced in percentage or in
erms of mean and median ± standard deviation. Survival was  cal-
ulated using the Kaplan Meier method, and for the evaluation of
he relationship between the explanatory variables was used the
rogram® XLSTAT—Kovach Computing Services. Anglesey, Wales.
K. The treatment of each patient was determined by the medical
taff of the Breast Unit, while the consent, signed by all the patients,
as approved by the Multidisciplinary Oncology Group and by the
thics Committee of the Hospital.PEN  ACCESS
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3. Results
3.1. Clinical features
Forty-seven patients at the Breast Unit of the Hospital “Santa
Maria” in Terni, Italy, with a diagnosis of breast cancer between
January 1995 and December 2014 were retrospectively analyzed
and evaluated in terms of general characteristics and survival. The
average age was  62 years (range 32–91 years). Family history of
breast cancer (HF) was observed in four cases. The main symp-
tom was  a solid sub areolar mass in 36 cases, 76%. The tumor was
associated with gynecomastia in two  cases (4%). Paget’s disease
was found in one case (2.5%). The median time for the consul-
tation was 28 months (range: 3–48 months). According to the
TNM classiﬁcation, tumors were classiﬁed as T1: 4 cases (9%),
T2: 9 (18.5%), T4 and T3, 25 and 9 cases, respectively, 52.5% and
20%. In 27 patients (57.2%), locally advanced disease was  classi-
ﬁed as N1, while in 25.2% of cases (12 patients) was  classiﬁed as
N2. Fourteen patients (30%) is presented with metastatic disease
already. He was diagnosed with invasive ductal carcinoma (IDC)
in 45 cases (95%); for the two  remaining cases this was inﬁltrat-
ing ductal carcinoma with Paget’s disease of the breast (2.5%) and
inﬁltrating lobular carcinoma (ILC) (2.5%). According to the classi-
ﬁcation Scarff-Bloom–Richardson grade II or III was predominant
(82% of cases). Axillary lymph nodes containing metastases (N+) in
79.4% of cases (39 patients). In addition, hormonal receptors were
evaluated in twenty-three cases. Both estrogen receptor (ER) and
progesterone receptor (PR) were positive in 67% (31 patients).
4. Treatment
Thirty-four patients (71%) were treated with radical mastec-
tomy (RM), while the modiﬁed radical mastectomy (MRM) was
performed in three cases; in the other three cases was  performed
simple mastectomy (SM), without lymph node dissection, and in
only one case was  performed lumpectomy. In six patients (13%)
was determined only palliative treatment. All patients received
adjuvant therapy after surgery. Twenty-three patients of thirty-
four patients received radiation therapy; the median dose delivered
was 50 Gy to the breast, chest wall and regional lymph nodes.
Chemotherapy (anthracycline-based protocol, AC60 or FEC 100)
was given in the neoadjuvant situation in two cases, in adjuvant
situation in nine cases. Delivery chemotherapy increased second
special stage and axillary lymph node involvement. Nine cases
receive in palliative. Hormone therapy was  delivered in twenty
patients adjuvant situation: tamoxifen alone in 20 cases, Tamox-
ifen with orchiectomy in one case. Six patients received palliative.
Table 2 summarizes the methods of treatment according to the TNM
stage. During the median follow-up of 38 months (3–168 months);
evolution has been characterized by local recurrences in eight cases
(17% of all patients). Metastasis occurred in 15 cases (32% of all
patients). The site of bone metastases was in six cases; lung in four
cases; liver in two  cases; liver and skin in one case and pleura and
skin in one case. The 5 and 10 year overall survival (OS) rates were
63% and 55%.
5. Discussion
Male breast cancer has many similarities to breast cancer in
women, but there are distinct functions that need to be appreciated.
In recent years, there has been an increase in the incidence of this
disease. Review of Surveillance, Epidemiology and End Result data
(SEER) indicate an increased incidence of male breast cancer, from
1.0 per 100,000 men  in the late 1970s to 1.2 per 100,000 men  from
2000 to 2004 [1,2] ; this value of incidence has increased steadily,
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o that in some countries have already led to 1.4 per 100,000 men.
he average age at diagnosis for men  with breast cancer is 67
ears, which is about 5–10 years the average age at diagnosis for
omen [1,3]. The average age of our patients (62 years) is slightly
ower than that of other series. The male breast cancer is probably
aused by the concomitant effects of various risk factors, including
linical disorders related to hormonal imbalances, some occupa-
ional exposures and environmental and genetic risk factors, for
xample, a family history of breast cancer and mutations in the
reast cancer predisposing genes, like the BRCA genes, and possi-
ly other [3]. Similar to breast cancer in women, MBC  is likely to be
aused by the concurrent effects of different risk factors, including
linical disorders relating to hormonal imbalances, certain occupa-
ional and environmental exposures, and genetic risk factors, for
nstance a positive family history (FH) of breast cancer (BC) and
utations in BC predisposing genes, such as BRCA genes, and pos-
ibly others. As is the case in female BCs, MBCs are highly sensitive
o hormonal changes. In particular, hormonal imbalance between
n excess of estrogen and a deﬁciency of testosterone increases the
isk of the disease. This imbalance may  occur endogenously due to
esticular abnormalities, including, undescended testes, congeni-
al inguinal hernia, orchitis, orchiectomy and testicular injury [10].
iver diseases, such as cirrhosis, may  also result in a hyperestro-
enic state [17]. In general, liver damage and disease, caused by
he effects of several drugs or their metabolites, may  affect hep-
tic functions and lead to hyperestrogenism. Obesity is one of the
ost common causes of hyperoestrogenization in men  because
f increased peripheral aromatization of androgens. Klinefelter’s
yndrome, characterized by 47XXY karyotype, testicular dysgene-
is, gynecomastia, low testosterone concentrations and increased
onadotrophins, is strongly associated with MBC  risk. Individuals
ith this syndrome have a 20–50 times higher risk over the gen-
ral male population [14]. An upset in estrogen or androgen balance
s a causal factor in gynecomastia, which is extremely common in
ubescent boys, may  occur in men  over the age of 50 and is found
n 6–38% of male pts affected by BC. However, the incidence of
ynecomastia in MBC  pts is no higher than in the general male
opulation [6]; gynecomastia, therefore, does not in itself seem
o represent a risk factor for MBC  [18,15]. As in women, ionizing
adiations have been considered as possible causal cofactors in the
tiology of MBC  [25,19]. Occupational exposure to heat and electro-
agnetic radiation are postulated to be linked to MBC  risk. A higher
requency of breast cancer is reported in men  who  have worked
n hot environments, such as blast furnaces, steel works, rolling
nd ﬁnishing mills [26,20], possibly because long-lasting exposure
o high ambient temperatures can lead to testicular failure. As for
omen, alcoholic beverages seem to represent a risk factor for the
evelopment of MBC, with an increase of 16% for each increase
f 10 g/day of alcohol intake. Moreover, strong consumers of alco-
olic beverages (more than 90 g/day) present a 6-fold increased
R to develop MBC  when compared to light consumers (<15 g/day)
28,21]. Overall, with the exception of alcohol consumption, dietary
actors seem to play a marginal role in the etiology of MBC. Simi-
ar to FBC, a positive FH of BC is associated with increased risk of
BC. Data from population-based studies have shown that about
0% of all MBC  pts have a history of BC in a ﬁrst-degree female
elative [17,22,12–16]. In general, a positive FH of either female or
ale breast cancer among ﬁrst-degree relatives confers a 2–3-fold
ncrease in MBC  risk [18,32,22–33]. The risk increases with increas-
ng numbers of ﬁrst-degree relatives affected and with early onset
n affected relatives. In addition to BC families, MBC  cases have also
een reported in families with the hereditary non-polyposis col-
rectal cancer (HNPCC) syndrome [34,24] and Cowden syndrome
35,25]. A personal history of a second primary tumor is reported in
ore than 11% of MBC  pts [36,26]. MBC  predisposition can result
rom germ-line mutations in the high-penetrance BRCA2 (OMIMPEN  ACCESS
Surgery Case Reports 20S (2016) 8–11
#6600185) and, with lower frequency, BRCA1 (OMIM  #113705)
genes. The presence of MBC  within high-risk BC families indicates
a high likelihood of BRCA2 mutations with a frequency ranging
from 60 to 76%, whereas BRCA1 mutations frequency ranges from
10 to 16% [40,27,41,28]. BRCA2 mutations are currently considered
as the major genetic risk factor for MBC, however, there is no evi-
dence for a correlation between the location of the mutation within
BRCA2 gene and risk of MBC. The median age at BC diagnosis among
BRCA2 mutation carriers is earlier (median, 58.8 years) than that of
negative cases (median, 67.9 years) [13]. Male carriers of BRCA2
germ-line mutations have a higher risk of developing BC than men
in the general population. Male BRCA2 mutation carriers have been
estimated to have a lifetime risk of 6.9% for developing BC, which is
approximately 80–100 times higher than in the general population
[62,29]. The most common clinical sign of breast cancer onset in
men  is a painless palpable swelling sub areolar [4]. Other symptoms
may  include involvement nipple, with retraction and/or ulcera-
tion and/or bleeding, axillary lymphadenopathy and gynecomastia
[3,4]. Because male breast lobules has not fully formed, the male
type of breast cancer is the most common invasive ductal carcinoma
(IDC) (85–95%) [4,5]. The result of our study was  comparable with a
ratio of 95% for IDC and this was  signiﬁcantly higher than the other
histological types. Lobular carcinoma in situ, Paget’s disease, and
inﬂammatory breast cancer have rarely been described in males [5].
Positivity rate receptor is more common in men  with breast cancer,
compared to women [30]. In several studies, ER and PR positivity
was reported 75–93% [31,32]. In our study, both the estrogen recep-
tor (ER) and progesterone receptor (PR) were positive in 67%. Breast
cancer in males should be treated with the same strategy in women
[33]. The most common surgical procedure is modiﬁed radical mas-
tectomy with axillary node dissection [34]. However, recent studies
are in favor of the amendment radical mastectomy or simple combi-
nation with radiotherapy. Postoperative radiotherapy does get local
control, but no effect was  observed on survival [35]. In men  treated
with mastectomy, adjuvant radiation therapy has been shown to
decrease local recurrence [36]. Tamoxifen has been shown to lead to
increased survival rates in women with hormone-sensitive disease
and today is generally considered the standard adjuvant treatment
for male breast cancer hormone-dependent [37]. The tolerance of
the drug has not been sufﬁciently studied in males, and its main side
effects are deep vein thrombosis, reduced libido, impotence, mood
swings and hot ﬂashes [38]. The chemotherapy should be used in
case of absence or doubt on endocrine-reactivity. Frequently used
chemotherapy regimens were CMF, FEC and EC [39]. The taxanes
may  be considered when the lymph nodes are involved. Regarding
the use of adjuvant trastuzumab, since there are no speciﬁc data,
its use should be considered based on the patient and tumor char-
acteristics [40]. The survival rate at 5 and 10 years overall patient
with male breast cancer are about 60 and 40%, respectively [41,42].
The number of histologically positive axillary lymph nodes and
tumor size were signiﬁcant prognostic factors. Another negative
prognostic factor is the advanced age at the time of diagnosis, as
the increased presence of comorbidities may  limit the possibility
of treatment.
6. Conclusion
The prognosis of the MBC  is undoubtedly worse of breast cancer
in women. Some researchers justify this by assuming a different
and greater biological aggressiveness. We believe, while recog-
nizing that much will be clariﬁed by a better knowledge of their
genetic engineering and epigenetic, extremely important collection
of studies and pilot retrospective series. Efforts to develop random-
ized, prospective studies in cooperative groups and other consortia
clinical trials are essential.
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